Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
UNICANCER
OHSU Knight Cancer Institute
Jules Bordet Institute
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research